Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ann Oncol
; 34(8): 681-692, 2023 08.
Article
in En
| MEDLINE
| ID: mdl-37211045
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Guideline
Limits:
Female
/
Humans
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2023
Document type:
Article